T C Greiner
Overview
Explore the profile of T C Greiner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
56
Citations
4597
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bouska A, Zhang W, Gong Q, Iqbal J, Scuto A, Vose J, et al.
Leukemia
. 2016 Jul;
31(1):83-91.
PMID: 27389057
Follicular lymphoma (FL) is typically an indolent disease, but 30-40% of FL cases transform into an aggressive lymphoma (tFL) with a poor prognosis. To identify the genetic changes that drive...
2.
Rohr J, Guo S, Huo J, Bouska A, Lachel C, Li Y, et al.
Leukemia
. 2016 Jan;
30(5):1062-70.
PMID: 26719098
Peripheral T-cell lymphomas (PTCLs) comprise a heterogeneous group of mature T-cell neoplasms with a poor prognosis. Recently, mutations in TET2 and other epigenetic modifiers as well as RHOA have been...
3.
Mian M, Scandurra M, Chigrinova E, Shen Y, Inghirami G, Greiner T, et al.
Ann Oncol
. 2011 Jun;
23(3):729-735.
PMID: 21693768
Background: Deletions at 13q14.3 are common in chronic lymphocytic leukemia and are also present in diffuse large B-cell lymphomas (DLBCL) but never in immunodeficiency-related DLBCL. To characterize DLBCL with 13q14.3...
4.
Iqbal J, Weisenburger D, Chowdhury A, Tsai M, Srivastava G, Greiner T, et al.
Leukemia
. 2010 Nov;
25(2):348-58.
PMID: 21052088
Natural killer (NK) cell lymphomas/leukemias are rare neoplasms with an aggressive clinical behavior. The majority of the cases belong to extranodal NK/T-cell lymphoma, nasal type (ENKTL) in the current WHO...
5.
Lenz G, Wright G, Dave S, Xiao W, Powell J, Zhao H, et al.
N Engl J Med
. 2008 Nov;
359(22):2313-23.
PMID: 19038878
Background: The addition of rituximab to combination chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), or R-CHOP, has significantly improved the survival of patients with diffuse large-B-cell lymphoma. Whether gene-expression...
6.
Pike B, Greiner T, Wang X, Weisenburger D, Hsu Y, Renaud G, et al.
Leukemia
. 2008 Feb;
22(5):1035-43.
PMID: 18288132
In an initial epigenetic characterization of diffuse large B-cell lymphoma (DLBCL), we evaluated the DNA methylation levels of over 500 CpG islands. Twelve CpG islands (AR, CDKN1C, DLC1, DRD2, GATA4,...
7.
Wang P, Lushnikova T, Odvody J, Greiner T, Jones S, Eischen C
Oncogene
. 2007 Sep;
27(11):1590-8.
PMID: 17828300
Mdm2, a regulator of the p53 tumor suppressor, is frequently overexpressed in lymphomas, including lymphomas that have inactivated p53. However, the biological consequences of Mdm2 overexpression in lymphocytes are not...
8.
Iqbal J, Greiner T, Patel K, Dave B, Smith L, Ji J, et al.
Leukemia
. 2007 Jul;
21(11):2332-43.
PMID: 17625604
Gene expression profiling of diffuse large B-cell lymphoma (DLBCL) has revealed biologically and prognostically distinct subgroups: germinal center B-cell-like (GCB), activated B-cell-like (ABC) and primary mediastinal (PM) DLBCL. The BCL6...
9.
Wang P, Greiner T, Lushnikova T, Eischen C
Oncogene
. 2006 Feb;
25(26):3708-18.
PMID: 16491126
The tumor suppressor p14/p19(ARF) regulates Mdm2, which is known for controlling the p53 tumor suppressor. Here we report that loss of one allele of Mdm2 in cells that lack ARF...
10.
Sharp J, Bishop M, Copple B, Greiner T, Iversen P, Jackson J, et al.
Leuk Lymphoma
. 2001 Nov;
42(3):417-27.
PMID: 11699407
Oligonucleotides offer the potential to manipulate gene expression in targeted cells which might be exploitable for therapeutic benefit. The effects of combining a phosphorothioate oligonucleotide OL(1) p53, which transiently down-regulates...